Skip to content

OSR HEALTH, INC.: 10-Q filed 2023-08-14

What OSR HEALTH, INC. reported in its quarterly report filed 2023-08-14 (fiscal Q2 2023): 21 published measures, 60 facts as tagged in accession 0000898432-23-000624.

This filing

Form
10-Q (quarterly report)
Filed
2023-08-14
Fiscal period
fiscal Q2 2023
Accession
0000898432-23-000624 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All OSR HEALTH, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2023-06-3071,494,506USD
At 2022-12-311,225,854USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2023-06-302,611,371USD
At 2022-12-311,263,362USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2023-06-30-2,094,509USD
At 2023-03-31-1,830,236USD
At 2022-12-31-37,508USD
At 2022-06-30-3,234USD
At 2022-03-31-2,246USD
At 2021-12-31-2,120USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2023-06-301,181USD
At 2022-12-31124,501USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2023-04-01 to 2023-06-30301,464USD91
2023-01-01 to 2023-06-30411,769USD181
2023-01-01 to 2023-03-31110,305USD90
2022-04-01 to 2022-06-30-988USD91
2022-01-01 to 2022-06-30-1,114USD181
2022-01-01 to 2022-03-31-126USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-01-01 to 2023-06-30-396,047USD181
2022-01-01 to 2022-06-30-7,073USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-01-01 to 2023-06-3070,480,227USD181
2022-01-01 to 2022-06-3076,490USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2023-01-01 to 2023-06-30-70,207,500USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2023-06-30-2,094,725USD
At 2022-12-31-62,508USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2023-04-01 to 2023-06-309,055,000shares91
2023-01-01 to 2023-06-307,133,177shares181
2022-04-01 to 2022-06-301,500,000shares91
2022-01-01 to 2022-06-301,500,000shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2023-04-01 to 2023-06-309,055,000shares91
2023-01-01 to 2023-06-307,196,575shares181
2022-04-01 to 2022-06-301,500,000shares91
2022-01-01 to 2022-06-301,500,000shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2023-04-01 to 2023-06-300.03USD/shares91
2023-01-01 to 2023-06-300.06USD/shares181
2022-04-01 to 2022-06-300USD/shares91
2022-01-01 to 2022-06-300USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2023-04-01 to 2023-06-300.03USD/shares91
2023-01-01 to 2023-06-300.06USD/shares181
2022-04-01 to 2022-06-300USD/shares91
2022-01-01 to 2022-06-300USD/shares181

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2023-04-01 to 2023-06-30228,565USD91
2023-01-01 to 2023-06-30257,886USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2023-06-3058,976USD
At 2022-12-31124,501USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2023-06-30541,371USD
At 2022-12-311,263,362USD

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2023-04-01 to 2023-06-30280,273USD91
2023-01-01 to 2023-06-30558,375USD181
2022-04-01 to 2022-06-30988USD91
2022-01-01 to 2022-06-301,114USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2023-06-302,155,000shares
At 2022-12-311,725,000shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2023-06-301,181USD
At 2022-12-31124,501USD
At 2022-06-3074,174USD
At 2021-12-314,757USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2022-12-3124,827USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2023-01-01 to 2023-06-30-411,769USD181
2022-01-01 to 2022-06-301,114USD181

Inspect the source

Entity
OSR HEALTH, INC. / CIK 0001840425
Captured
2026-09-21T17:37:27.107Z
SEC response SHA-256
a0d30433e6a20a35440697935a5f38c30b52570c7afa4a92b7b1c23550f84d90

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001840425.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))